N
Nordicus Partners Corp
NORDCIK 0001011060OTCNon-AcceleratedSmaller ReportingServices-Management Consulting ServicesDelawareHKFY ends Mar 31
Period
FY 2026
Revenue
—
Net Income
$-4.00M
Total Assets
$75.46M
Equity
$64.28M
Shares Out
19.17M
Op. Cash Flow
$-4.32M
Business
Nordicus Partners Corporation is a biotech company acquiring and developing breakthrough therapeutics for unmet medical needs in oral disorders and immune conditions. The company scouts early-stage Nordic life sciences firms and acquires controlling stakes to advance drug candidates. Its portfolio includes three subsidiaries: Orocidin A/S developing QR-01 for periodontitis, Bio-Convert A/S developing QR-02 for oral leukoplakia, and NoviThera ApS developing QR-04 for psoriasis, with candidates in preclinical and early clinical stages.
Summary from 10-K filed 2026-07-14
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Revenue | — | 5,000 | |
| Operating expenses: | — | — | |
| Officer compensation | 615,284 | 662,554 | |
| Professional Fees | 940,727 | 351,773 | |
| Consulting expense | 317,960 | 248,878 | |
| Selling, General and Administrative Expense | 890,055 | 331,724 | |
| Research and Development Expense | 2 | 1 | |
| Total operating expenses | 4 | 3 | |
| Loss from operations | −4 | −3 | |
| Other (expense) income: | — | — | |
| Interest expense | 642 | 200 | |
| Change in fair value of warrant liability (related party) | — | 172,715 | |
| Gain/Loss on Investments | 325,000 | 175,000 | |
| Other expense | 164 | — | |
| Total other (expense) income | 324,194 | 2,085 | |
| Loss before provision for income taxes | −4 | −3 | |
| Income Tax Expense | — | — | |
| Net loss | −4 | −3 | |
| Net Income Attributable to Noncontrolling Interest | −45,118 | −15,959 | |
| Net loss attributable to Nordicus Partners Corporation | −4 | −3 | |
| Other comprehensive income (loss): | — | — | |
| Foreign currency translation adjustment | 4 | 618,233 | |
| Comprehensive income (loss) | −301,613 | −2 | |
| Net comprehensive income attributable to noncontrolling interests | 559 | — | |
| Comprehensive income (loss) attributable to Nordicus Partners Corporation | −302,172 | −2 | |
| Earnings Per Share (Basic) | −0.22 | −0.32 | |
| Earnings Per Share (Diluted) | −0.22 | −0.32 | |
| Weighted Average Shares Outstanding | 18 | 9 | |
| Weighted Average Shares Outstanding, Diluted | 18 | 9 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| ASSETS | — | — | |
| Current assets: | — | — | |
| Cash and Cash Equivalents | 20,878 | 19,914 | |
| Other Non-Operating Current Assets | 512,006 | 37,656 | |
| Total current assets | 532,884 | 57,570 | |
| In-process research and development | 46 | 43 | |
| Property, Plant and Equipment | 8,207 | — | |
| Goodwill | 27 | 25 | |
| Long-Term Investments | 2 | 2 | |
| Other Non-Operating Non-Current Assets | 4,784 | 64,929 | |
| Total assets | 75 | 70 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | — | — | |
| Current liabilities: | — | — | |
| Accounts Payable | 1 | 1 | |
| Short-Term Debt | 60,000 | — | |
| Total current liabilities | 1 | 1 | |
| Deferred Tax Liabilities, Current | 10 | 9 | |
| Total liabilities | 11 | 10 | |
| Commitments and contingencies | — | — | |
| Stockholders’ equity: | — | — | |
| Preferred Stock | — | — | |
| Total Stockholders' Equity | 19,187 | 17,253 | |
| Treasury stock; 57,796 and 154 shares at cost at March 31, 2026 and March 31, 2025, respectively | 108,722 | 30,328 | |
| Additional Paid-In Capital | 111 | 106 | |
| Accumulated Other Comprehensive Income | 4 | 615,385 | |
| Retained Earnings | −51 | −47 | |
| Total equity attributed to the parent | 64 | 60 | |
| Noncontrolling Interest | −43,777 | — | |
| Total stockholders’ equity | 64 | 60 | |
| Total liabilities and stockholders’ equity | 75 | 70 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| Cash flows from operating activities: | — | — | |
| Profit or Loss | −4 | −3 | |
| Shares issued for services | 304,800 | 138,979 | |
| Stock-based compensation | 137,544 | 527,625 | |
| Non-Operating Income (Expense) | — | 172,715 | |
| Loss on sale of assets | −163 | — | |
| Change in fair value of investment | 325,000 | 175,000 | |
| Non-cash expense of IPR&D | 1,559 | — | |
| Goodwill Impairment | 5,198 | 5,174 | |
| Changes in assets and liabilities: | — | — | |
| Prepaid expenses and other current assets | 403,553 | 8,784 | |
| Other assets | 1,160 | 60,089 | |
| Accounts payable and accrued expenses | −81,637 | 1 | |
| Foreign currency remeasurement | −84,115 | — | |
| Net cash used in operating activities | −4 | −1 | |
| Cash flows from investing activities: | — | — | |
| Proceeds from Sale of PP&E | 7,597 | — | |
| Purchase of plant, property, and equipment | 17,755 | — | |
| Cash paid for website costs | — | 2,374 | |
| Net Cash from Investing Activities | — | 150,186 | |
| Net cash (used in) provided by investing activities | −10,158 | 147,812 | |
| Cash flows from financing activities: | — | — | |
| Cash paid for stock issuance costs in business combinations | — | 2,880 | |
| Repurchase of common stock | 78,394 | — | |
| Gross proceeds | 4 | — | |
| Proceeds from Debt Issuance | 60,000 | — | |
| Net Cash from Financing Activities | — | 193,330 | |
| Net Cash from Financing Activities | — | 889,477 | |
| Net cash provided by financing activities | 4 | 1 | |
| Net change in cash | 515 | −56,876 | |
| Effect of Exchange Rate on Cash | 449 | 26,857 | |
| Cash at beginning of period | 19,914 | 49,933 | |
| Cash at end of period | 20,878 | 19,914 | |
| Supplemental disclosure of cash flow information: | — | — | |
| Income Tax Expense | — | — | |
| Interest Expense | — | — | |
| Supplemental disclosures of non-cash information: | — | — | |
| NoviThera equity issued for intellectual property | 1,568 | — | |
| Common Stock issued for the acquisition of Bio-Convert | — | 39 | |
| Net Cash from Financing Activities | — | 19 | |
| Cancellation of liability-classified warrants – related party | — | 167,000 | |
| Forgiveness of debt - related party | — | 13,886 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Nordicus Partners Corp's CIK number?
Nordicus Partners Corp's SEC CIK number is 0001011060 (1011060). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Nordicus Partners Corp's SEC filings?
All of Nordicus Partners Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.